GB201617599D0 - MLV-based gene therapy with mutated integrase coupled to peptides - Google Patents

MLV-based gene therapy with mutated integrase coupled to peptides

Info

Publication number
GB201617599D0
GB201617599D0 GBGB1617599.4A GB201617599A GB201617599D0 GB 201617599 D0 GB201617599 D0 GB 201617599D0 GB 201617599 A GB201617599 A GB 201617599A GB 201617599 D0 GB201617599 D0 GB 201617599D0
Authority
GB
United Kingdom
Prior art keywords
mlv
peptides
coupled
gene therapy
based gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1617599.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katholieke Universiteit Leuven
Original Assignee
Katholieke Universiteit Leuven
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Universiteit Leuven filed Critical Katholieke Universiteit Leuven
Priority to GBGB1617599.4A priority Critical patent/GB201617599D0/en
Publication of GB201617599D0 publication Critical patent/GB201617599D0/en
Priority to PCT/EP2017/076615 priority patent/WO2018073307A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
GBGB1617599.4A 2016-10-18 2016-10-18 MLV-based gene therapy with mutated integrase coupled to peptides Ceased GB201617599D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1617599.4A GB201617599D0 (en) 2016-10-18 2016-10-18 MLV-based gene therapy with mutated integrase coupled to peptides
PCT/EP2017/076615 WO2018073307A1 (en) 2016-10-18 2017-10-18 Mlv-based gene therapy with mutated integrase coupled to peptides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1617599.4A GB201617599D0 (en) 2016-10-18 2016-10-18 MLV-based gene therapy with mutated integrase coupled to peptides

Publications (1)

Publication Number Publication Date
GB201617599D0 true GB201617599D0 (en) 2016-11-30

Family

ID=57680780

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1617599.4A Ceased GB201617599D0 (en) 2016-10-18 2016-10-18 MLV-based gene therapy with mutated integrase coupled to peptides

Country Status (2)

Country Link
GB (1) GB201617599D0 (en)
WO (1) WO2018073307A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482587B1 (en) * 1999-10-01 2002-11-19 The Regents Of The University Of Michigan Methods to inhibit or enhance the binding of viral DNA to genomic host DNA
WO2016176152A2 (en) * 2015-04-25 2016-11-03 Washington State University Re-targeted foamy virus vectors

Also Published As

Publication number Publication date
WO2018073307A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
GB2607227B (en) Viral methods of T cell therapy
IL276679B (en) Viral resistant cells and uses thereof
IL284577A (en) Gene therapy
ZA201604874B (en) Rna-guided gene drives
IL251468A0 (en) Aav-based gene therapy
EP3094342A4 (en) Anti-tumor therapy
GB201420139D0 (en) Factor IX gene therapy
EP3138906A4 (en) Cd82-positive cardiac progenitor cells
GB201407322D0 (en) Gene therapy
ZA201808121B (en) Therapeutic hpv vaccine combinations
RS62619B1 (en) Gene therapy
GB2565497B (en) Microbattery with through-silicon via electrodes
EP3096777A4 (en) Goblet cell replacement therapy
GB201617599D0 (en) MLV-based gene therapy with mutated integrase coupled to peptides
GB201701968D0 (en) Gene therapy
GB201414542D0 (en) Novel therapy
GB201408962D0 (en) Electrode array
IL263085A (en) Gene therapy
GB201616821D0 (en) Gene therapy
GB201612105D0 (en) Gene therapy
GB201612104D0 (en) Gene therapy
GB201621874D0 (en) Therapeutic Cells
GB201601720D0 (en) Improved photo-bioreactor design
GB201704634D0 (en) Gene therapy
GB201410595D0 (en) Factor IX gene therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)